Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
暂无分享，去创建一个
A. Bravard | R. Descourt | R. Lamy | O. Bylicki | E. Huchot | R. Schott | G. Justeau | C. Chouaid | C. Locher | J. Le Treut | G. Le Garff | M. Roa | D. Moreau | C. Bernier | G. De chabot | M. Tiercin | Y. Simonneau | Adina Marty | Gonzague De chabot | Y. Simonneau
[1] L. Mazzucchelli,et al. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy , 2022, Journal of clinical medicine.
[2] G. Barnett,et al. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases , 2021, Scientific Reports.
[3] Maarten J. IJzerman,et al. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. , 2020, Lung cancer.
[4] Pingli Wang,et al. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis , 2017, Oncotarget.
[5] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[6] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[7] Jean Mosser,et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.
[8] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[9] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.